Study summary

Low-dose aspirin halved recurrence in cancers with PI3K-pathway mutations

ALASCCA trial (aspirin) · 626 people, phase 3 · Published September 2025, New England Journal of Medicine

7.7%recurrence at 3 years, vs 14.1% with placebo

What was tested

Aspirin 160 mg daily or placebo for 3 years after treatment for stage I to III colorectal cancer with PIK3CA or other PI3K-pathway mutations (about 1 in 3 tumors).

What they found

What it means

Tumor testing for PI3K-pathway mutations may guide aspirin use; a separate trial after liver metastases found no benefit.

N Engl J Med, via PubMed ↗ Trial record NCT02647099 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.